Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
114.70    1.50 (1.33%)
Bid:
115.00
Ask:
115.50
Spread: 0.50 (0.435%)
Market Cap: £1.12b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

Block Admission Application

26 Mar 2026 15:00

RNS Number : 3093Y
Oxford Nanopore Technologies plc
26 March 2026
 

26 March 2026

Oxford Nanopore Technologies plc (the "Company")

Block Admission Application

The Company confirms that a new block admission application (the "New Block Admission Application") has been made to the London Stock Exchange for 50,000,000 ordinary shares of £0.0001 each in the capital of the Company (the "New Ordinary Shares") to be admitted to trading on the London Stock Exchange's main market for listed securities.

The New Ordinary Shares will, upon issue, rank equally with all other ordinary shares of £0.0001 each in the capital of the Company ("Ordinary Shares") that are then in issue.

The New Ordinary Shares will be issued by the Company from time to time under the terms of the following remuneration plans:

- the Oxford Nanopore Technologies Limited Share Option Scheme;

- the Oxford Nanopore Technologies Limited Share Option Plan 2018;

- the Oxford Nanopore Technologies Limited Long-Term Incentive Plan 2021;

- the Oxford Nanopore Technologies plc Long-Term Incentive Plan 2021;

- the Oxford Nanopore Technologies plc Deferred Bonus Plan 2021;

- the Oxford Nanopore Technologies plc Share Incentive Plan 2021; and

- the Oxford Nanopore Technologies plc Employee Stock Purchase Plan 2021.

The New Block Admission Application is in addition to the Company's existing block admission of 40,000,000 Ordinary Shares announced on 5 October 2021 (the "Existing Block Admission"). Currently, 5,160,512 Ordinary Shares remain subject to its Existing Block Admission.

It is expected that admission of the New Ordinary Shares will become effective on 30 March 2026.

Enquiries:

Investors

ir@nanoporetech.com 

Media 

media@nanoporetech.com

OxfordNanoporeTechnologies@teneo.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZZGZFZVFGVZM
Date   Source Headline
1st Aug 20225:30 pmRNSIssue of Equity and Total Voting Rights
12th Jul 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Jul 20227:00 amRNSSale and leaseback of headquarters building
1st Jul 20225:16 pmRNSIssue of Equity and Total Voting Rights
30th Jun 20227:15 amRNSDuncan Tatton-Brown appointed as Non-Exec Chair
23rd Jun 20224:30 pmRNSResult of AGM
13th Jun 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Jun 20224:00 pmRNSIssue of Equity and Total Voting Rights
31st May 20226:30 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSONT releases Remora:most comprehensive methylation
20th May 20227:00 amRNSOxford Nanopore announces tech updates
19th May 20229:06 amRNSONT opens user conference, rich science programme
13th May 20227:00 amRNSONT chosen for comprehensive human genome program
11th May 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
3rd May 20224:00 pmRNSIssue of Equity and Total Voting Rights
12th Apr 20226:15 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Apr 20221:01 pmRNSDirector/PDMR Shareholding
12th Apr 20221:01 pmRNSDirector/PDMR Shareholding
12th Apr 20221:00 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSPublication of Annual Report and Notice of AGM
6th Apr 20221:00 pmRNSBlock listing Interim Review
5th Apr 202211:00 amRNSDirector/PDMR Shareholding
4th Apr 20222:00 pmRNSGenomics England expands Nanopore use in cancer
1st Apr 20225:00 pmRNSIssue of Equity and Total Voting Rights
1st Apr 20227:00 amRNSAgreement
30th Mar 20222:00 pmRNSONT shows new high-accuracy, high-output chemistry
24th Mar 20227:00 amRNSNanopore sequencing profiles TB: FIND evaluation
23rd Mar 20222:02 pmRNSOxford Nanopore releases Short Fragment Mode
22nd Mar 20227:00 amRNSPreliminary Results and Guidance Update
11th Mar 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 20227:03 amRNSPublication: Nanopore IDs >50 genetic diseases
1st Mar 20225:00 pmRNSIssue of Equity and Total Voting Rights
24th Feb 20227:00 amRNSNotice of Results
11th Feb 20225:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Feb 20225:00 pmRNSIssue of Equity and Total Voting Rights
24th Jan 20223:00 pmRNSAppointment of Senior Independent Director
18th Jan 20221:00 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSFastest human genome sequence uses Oxford Nanopore
11th Jan 20226:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Jan 202212:00 pmRNSUpdate to FY21 revenue guidance
7th Jan 20227:00 amRNSCompany to present at JP Morgan Healthcare conf
4th Jan 20226:30 pmRNSIssue of Equity and Total Voting Rights
20th Dec 20215:00 pmRNSHolding(s) in Company
13th Dec 20216:15 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Dec 20217:00 amRNSOxford Nanopore announces technology updates
1st Dec 20217:00 amRNSIssue of Equity and Total Voting Rights
9th Nov 20217:03 amRNSUpdate to revenue guidance
3rd Nov 20216:00 pmRNSHolding(s) in Company
1st Nov 20216:30 pmRNSPDMR Notification (ESPP) and Director Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.